Post‐transfusion biotin‐labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance
Transfusion · 2024
DOI: 10.1111/trf.17800 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2024. Verfasst von Marianne E M Yee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Erythrocytes, Biotin, Autoantibodies. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Red blood cell (RBC) antibodies are common in multiply transfused patients with sickle cell disease (SCD). Unlike RBC alloantibodies, the potential of autoantibodies to cause post‐transfusion hemolysis may be uncertain. Biotin‐labeling provides a direct measurement of red cell survival (RCS) over time, thus can be used to assess the clinical significance of RBC antibodies. Antibodies to biotinylated RBC (B‐RBC) occasionally are detected after exposure, which may impact B‐RBC survival in subsequent RCS studies. Study Design and Methods Pediatric patients with SCD receiving monthly chronic transfusions underwent RCS studies, receiving aliquots of allogeneic RBC labeled at distinct densities of biotin (2–18 μg/mL). B‐RBC survival was followed for 4 months post‐transfusion, and B‐RBC antibody screening for 6 months. Patients with warm autoantibodies (WAA) or B‐RBC antibodies are reported here.
Results
RBC antibodies were detected during RCS in four patients: one with WAA, one with WAA followed by B‐RBC‐specific antibodies, and two with transient B‐RBC antibodies within the first 5 weeks of exposure. B‐RBC half‐lives (T 50 ) ranged 37.6–61.7 days (mean 47.8 days). There was no evidence of increased hemolysis or accelerated B‐RBC clearance in the presence of WAA or B‐RBC antibodies.
Discussion
Biotinylation of allogenic RBC can be used to assess the possible effects of RBC antibodies on transfusion survival in individual cases, particularly when it is uncertain if the detected antibodies may result in hemolysis. In the cases presented here, neither WAA nor B‐RBC antibodies were associated with significant shortening of B‐RBC survival in individuals with SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
- Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
- Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Medical Services, Lifesouth Community Blood Centers, Gainesville, Florida, USA.
- Transfusion Services, Northside Hospital, Atlanta, Georgia, USA.
ORCID-Profile: Marianne E M Yee, Mischa L Covington, Sean R Stowell, Ross M Fasano
Förderung
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Yee, M. E. M., Zerra, P. E., McCoy, J. W., Covington, M. L., Stowell, S. R., Joiner, C. H., Lough, C. M., Delvadia, B. B., Josephson, C. D., Roback, J. D., & Fasano, R. M. (2024). Post‐transfusion biotin‐labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance. Transfusion. https://doi.org/10.1111/trf.17800
Vancouver
Yee MEM, Zerra PE, McCoy JW, Covington ML, Stowell SR, Joiner CH, et al. Post‐transfusion biotin‐labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance. Transfusion. 2024. doi:10.1111/trf.17800
BibTeX
@article{Yee2024,
author = {Yee, Marianne E M and Zerra, Patricia E and McCoy, James W and Covington, Mischa L and Stowell, Sean R and Joiner, Clinton H and Lough, Christopher M and Delvadia, Bhaveshkumar B and Josephson, Cassandra D and Roback, John D and Fasano, Ross M},
title = {Post‐transfusion biotin‐labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance},
journal = {Transfusion},
year = {2024},
doi = {10.1111/trf.17800}
}
EUVIMED